Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.
An estimated 8 million persons, mainly in Latin America, are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease. Existing antiparasitic drugs for Chagas disease have significant toxicities and suboptimal effectiveness, hence new therapeutic strategies need to be devised to addres...
Saved in:
Main Authors: | Joseph D Planer (Author), Matthew A Hulverson (Author), Jennifer A Arif (Author), Ranae M Ranade (Author), Robert Don (Author), Frederick S Buckner (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2014-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023) -
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
by: Ahmed Mostafa, et al.
Published: (2020) -
FDA approved injection drug against schizophrenia
by: article Editorial
Published: (2023) -
FDA-approved drugs in 2022: A brief outline
by: Haitham Ahmed Al-Madhagi
Published: (2023) -
Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
by: Hasan Afzaal, et al.
Published: (2022)